Special Issues
Table of Content

Gastroenteropancreatic Tumors: From Basic Research to Therapeutic Approach

Submission Deadline: 28 February 2026 (closed) View: 922 Submit to Journal

Guest Editors

Prof. Simona Gurzu

Email: simonagurzu@yahoo.com

Affiliation: Department of Pathology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, Targu Mures, 540139, Romania.

Homepage:

Research Interests: Pathology, molecular biology, immunohistochemistry, targeted therapy, gastroenteropancreatic tumors

图片1.png


Dr. Zsolt Kovacs

Email: kovacska_zsoltkovacs@yahoo.com

Affiliation: Department of Biochemistry and Environmental Chemistry, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, Târgu Mureș, 540139, Romania.

Homepage:

Research Interests: Medical genetics, Bioinformatics, Molecular biology

图片2.png


Summary

The spectrum of gastroenteropancreatic tumors is continuously enlarged, from their microscopic architecture to therapeutic challenges. Although the era of molecular biology is evolving, few molecular therapeutic options are available for their cure. The present special issue aims to include new perspectives on these tumors, from biomarkers to clinical aspects and trials. The papers should highlight the multidisciplinary approach to the tumors of the gastrointestinal tract, along with pancreatic cancer, hepatocellular carcinoma, cholangiocarcinoma, or gallbladder tumors. Experimental research is also welcome. The final aim is to show a picture of the old and new concepts for approaching gastroenteropancreatic tumors, from tumorigenesis to oncologic therapy.


Keywords

colorectal cancer, gastric cancer, pancreatic tumors, hepatocellular carcinoma, neuroendocrine tumors

Published Papers


  • Open Access

    ARTICLE

    Claudin 18.2 Expression in Gastric Adenocarcinoma: Diagnostic Reproducibility and Clinicopathologic Associations in A Western Cohort

    Cristina Díaz del Arco, Luis Ortega Medina, Patricia Barreiro Sanabria, Andrés Sánchez Pernaute, Lourdes Estrada Muñoz, Elena Molina Roldán, María Jesús Fernández Aceñero
    Oncology Research, DOI:10.32604/or.2026.075609
    (This article belongs to the Special Issue: Gastroenteropancreatic Tumors: From Basic Research to Therapeutic Approach)
    Abstract Background: Claudin 18.2 (CLDN18.2) has become a clinically relevant therapeutic target in gastric adenocarcinoma (GC), with zolbetuximab now approved for use in CLDN18.2-positive, HER2-negative advanced disease. The aim of this study was to evaluate the prevalence, intratumoral reproducibility, and clinicopathologic associations of CLDN18.2 expression in a Western cohort of resected GC. Methods: CLDN18.2 expression was evaluated by immunohistochemistry in 204 resected GCs arranged in tissue microarrays containing duplicate tumor cores corresponding to the tumor center and invasive front. Correlations between paired cores, clinicopathologic parameters, additional biomarkers (E-cadherin, HER2, p53, mismatch repair (MMR)), and clinical outcomes were… More >

  • Open Access

    REVIEW

    Current Advances in Preclinical Patient-Derived Cultivation Models for Individualized Drug Response Prediction in Pancreatic Cancer

    Benjamin Heckelmann, Jannis Duhn, Rüdiger Braun
    Oncology Research, DOI:10.32604/or.2026.075028
    (This article belongs to the Special Issue: Gastroenteropancreatic Tumors: From Basic Research to Therapeutic Approach)
    Abstract Pancreatic ductal adenocarcinoma (PDAC) is currently the third leading cancer-related cause of death worldwide and is forecasted to become the second leading cause in the United States by 2030. Despite the development of multimodal treatment regimens, 5-year overall survival remained as low as 12%. Several efforts have been made to account for different aspects of heterogeneous tumor biology in PDAC, aiming to enable treatment stratification of defined subtypes. Besides targeting specific mutations, the definition of molecular (transcriptional) subtypes has gained substantial interest regarding response prediction and treatment stratification. Despite numerous advances in the field of… More >

Share Link